Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Gains from Investment Securities (2018 - 2022)

Endonovo Therapeutics has reported Gains from Investment Securities over the past 5 years, most recently at $513730.0 for Q2 2022.

  • Quarterly results put Gains from Investment Securities at $513730.0 for Q2 2022, changed N/A from a year ago — trailing twelve months through Jun 2022 was $513730.0 (changed N/A YoY), and the annual figure for FY2021 was $513730.0, up 13.63%.
  • Gains from Investment Securities for Q2 2022 was $513730.0 at Endonovo Therapeutics, roughly flat from $513730.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for ENDV hit a ceiling of $93.2 million in Q2 2018 and a floor of $3300.0 in Q2 2020.
  • Median Gains from Investment Securities over the past 5 years was $513730.0 (2021), compared with a mean of $14.0 million.